Lilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda

Eli Lilly and Company has issued the following statement in response to the verdict in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. No. 6:12-cv-00064.

The jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Lilly.

"While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, Senior Vice President and General Counsel. "Lilly disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means."

Judgments were entered in Takeda's favor in all three previous Actos trials. Lilly was not named previously. This is the first federal case to be tried and the first in the consolidated Actos multidistrict litigation (MDL). Lilly copromoted Actos with Takeda from 1999 to 2006.  

Under Lilly's agreement with Takeda, Lilly will be indemnified by Takeda for its losses and expenses with respect to the US litigation and other related expenses in accordance with the terms of its indemnification agreement.